Selecta Biosciences (NASDAQ:SELB) issued its quarterly earnings results on Thursday. The company reported ($0.71) EPS for the quarter, beating the consensus estimate of ($0.79) by $0.08, MarketWatch Earnings reports.

SELB stock traded down $0.29 during mid-day trading on Friday, reaching $5.51. The company had a trading volume of 347,760 shares, compared to its average volume of 444,699. The company has a debt-to-equity ratio of 0.87, a current ratio of 4.96 and a quick ratio of 4.96. The company has a market capitalization of $129.90 million, a P/E ratio of -1.72 and a beta of 0.91. Selecta Biosciences has a 12 month low of $4.74 and a 12 month high of $16.55.

Several brokerages recently commented on SELB. UBS Group set a $6.00 price target on shares of Selecta Biosciences and gave the company a “hold” rating in a report on Friday. BidaskClub downgraded shares of Selecta Biosciences from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, July 25th. Mizuho restated a “buy” rating and issued a $30.00 target price on shares of Selecta Biosciences in a research note on Monday, November 5th. Zacks Investment Research upgraded shares of Selecta Biosciences from a “sell” rating to a “hold” rating in a research note on Wednesday, October 10th. Finally, Stifel Nicolaus initiated coverage on shares of Selecta Biosciences in a research note on Friday, September 14th. They issued a “buy” rating and a $24.00 target price on the stock. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and four have given a buy rating to the company. Selecta Biosciences presently has a consensus rating of “Hold” and an average price target of $23.83.

A number of hedge funds have recently modified their holdings of the business. BlackRock Inc. grew its stake in Selecta Biosciences by 1.5% in the 3rd quarter. BlackRock Inc. now owns 897,480 shares of the company’s stock worth $13,956,000 after acquiring an additional 12,916 shares in the last quarter. Artal Group S.A. lifted its position in shares of Selecta Biosciences by 12.3% in the 3rd quarter. Artal Group S.A. now owns 561,540 shares of the company’s stock worth $8,732,000 after purchasing an additional 61,540 shares during the period. Wasatch Advisors Inc. lifted its position in shares of Selecta Biosciences by 9.2% in the 2nd quarter. Wasatch Advisors Inc. now owns 235,625 shares of the company’s stock worth $3,122,000 after purchasing an additional 19,803 shares during the period. Northern Trust Corp lifted its position in shares of Selecta Biosciences by 11.9% in the 2nd quarter. Northern Trust Corp now owns 156,708 shares of the company’s stock worth $2,076,000 after purchasing an additional 16,615 shares during the period. Finally, Millennium Management LLC purchased a new stake in shares of Selecta Biosciences in the 2nd quarter worth approximately $1,583,000. Institutional investors and hedge funds own 48.63% of the company’s stock.

WARNING: This article was originally reported by Daily Political and is the property of of Daily Political. If you are viewing this article on another site, it was copied illegally and republished in violation of United States & international copyright and trademark laws. The legal version of this article can be read at https://www.dailypolitical.com/2018/11/10/selecta-biosciences-selb-issues-quarterly-earnings-results-beats-estimates-by-0-08-eps.html.

Selecta Biosciences Company Profile

Selecta Biosciences, Inc, a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its proprietary pipeline includes synthetic vaccine particles (SPV)-enabled enzyme, oncology, and gene therapies. The company's lead product is SEL-212 that in Phase II clinical trial to treat severe gout patients and resolve their symptoms, including flares and gouty arthritis.

Featured Story: Return on Investment (ROI) Defined, Explained

Earnings History for Selecta Biosciences (NASDAQ:SELB)

Receive News & Ratings for Selecta Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.